Biotech

Category / Pharmaceuticals & Biotech / Biotech

Miraculins Announces Closing of Private Placement Offering

WINNIPEG, MANITOBA: ...

Epistem Presents Biomarker Data, and Its New Preclinical Model of Acute Myeloid Leukaemia, at the AACR 2013 Annual Meeting

MANCHESTER, UNITED KINGDOM: ...

Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

CAMBRIDGE, MA: Data to Be Presented at the Muscular Dystrophy Association Scientific Conference ...

Sernova Issues Additional Finder Warrants, Cancels Options

LONDON, ONTARIO: ...

Theratechnologies to Announce First Quarter 2013 Financial Results

MONTREAL, QUEBEC: ...

Acura Pharmaceuticals Awarded U.S. Patent for Abuse Deterrent Drug Formulations

PALATINE, IL: Further Expands Patent Estate Covering Abuse Deterrent Forms of Opioid Analgesics and Certain Other Active Pharmaceutical Ingredients ...

Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development

SAN DIEGO, CA: ...

Prana Announces $5.8 Million R&D Refund

MELBOURNE, AUSTRALIA: ...

Vital Therapies, Inc. Enrolls First Patient in VTI-208, a Controlled, Randomized Phase 3 Trial Evaluating the ELAD(R) System in Alcohol-Induced Liver Decompensation

SAN DIEGO, CA: ...

IDT Ltd Appoints Dr. Paul MacLeman CEO

MELBOURNE, AUSTRALIA: ...

Aragon Announces First Patient Dosed in Phase I Study of ARN-810 in Estrogen Receptor Positive Breast Cancer

SAN DIEGO, CA: ...

Aquinox Pharmaceuticals Completes US $18 million Series C Financing

VANCOUVER, BRITISH COLUMBIA: Positive Phase IIa Results Attract Additional Funds and New Syndicate Member to Advance Clinical Development and Strengthen Management Team ...

Arch Scientists Publish Data Linking Inflammatory Enzymes to Inflammatory Bowel Disease

TORONTO, ONTARIO: ...

Prana Provides Clinical Trials Safety and Progress Update

MELBOURNE, AUSTRALIA: Alzheimer's and Huntington Disease Trials on Track ...

Aquinox Pharmaceuticals Completes US $18 million Series C Financing

VANCOUVER, BRITISH COLUMBIA: Positive Phase IIa Results Attract Additional Funds and New Syndicate Member to Advance Clinical Development and Strengthen Management Team ...

ViroCyt Completes Second Close of Growth Capital Financing

DENVER, CO: ...

Calyx Majority-Owned Subsidiary, Agrisoma Biosciences Inc., Enters Into Marketing and Distribution Agreement With Subsidiary of Paterson Grain

VANCOUVER, BRITISH COLUMBIA: ...

Theratechnologies Inc.: Renegotiated Lease to Generate Substantial Annual Savings

MONTREAL, CANADA: ...

Critical Outcome Technologies Inc. Retains Market-Making Services

LONDON, ONTARIO: ...

Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting

TUSTIN, CA: ...

Page 145 von 247: 1 « .. 144 145 146 147 148 149 150 151 152 153 .. » 247

All members:	10 566
Register today:	1
Register yesterday:	0
Members online:	0
Guests online:	112

Biotech

Category / Pharmaceuticals & Biotech / Biotech

Miraculins Announces Closing of Private Placement Offering

Epistem Presents Biomarker Data, and Its New Preclinical Model of Acute Myeloid Leukaemia, at the AACR 2013 Annual Meeting

Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

Sernova Issues Additional Finder Warrants, Cancels Options

Theratechnologies to Announce First Quarter 2013 Financial Results

Acura Pharmaceuticals Awarded U.S. Patent for Abuse Deterrent Drug Formulations

Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development

Prana Announces $5.8 Million R&D Refund

Vital Therapies, Inc. Enrolls First Patient in VTI-208, a Controlled, Randomized Phase 3 Trial Evaluating the ELAD(R) System in Alcohol-Induced Liver Decompensation

IDT Ltd Appoints Dr. Paul MacLeman CEO

Aragon Announces First Patient Dosed in Phase I Study of ARN-810 in Estrogen Receptor Positive Breast Cancer

Aquinox Pharmaceuticals Completes US $18 million Series C Financing

Arch Scientists Publish Data Linking Inflammatory Enzymes to Inflammatory Bowel Disease

Prana Provides Clinical Trials Safety and Progress Update

Aquinox Pharmaceuticals Completes US $18 million Series C Financing

ViroCyt Completes Second Close of Growth Capital Financing

Calyx Majority-Owned Subsidiary, Agrisoma Biosciences Inc., Enters Into Marketing and Distribution Agreement With Subsidiary of Paterson Grain

Theratechnologies Inc.: Renegotiated Lease to Generate Substantial Annual Savings

Critical Outcome Technologies Inc. Retains Market-Making Services

Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting

Service Menu

New here

Who is online